Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 11/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | PRKCG | P05129 | 2/20 | 0.44 |
| ▸ | PRKCB | P05771 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 2/20 | 0.44 |
| ▸ | PRKCH | P24723 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288818 | 1.00 | ZAP70 (0.46) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4276714 | 0.92 | ZAP70 (0.54) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4291693 | 0.92 | ZAP70 (0.54) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4278615 | 0.91 | ZAP70 (0.55) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4282425 | 0.91 | ZAP70 (0.55) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4290659 | 0.91 | ZAP70 (0.55) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4282077 | 0.88 | ZAP70 (0.53) | ZAP70JAK2JAK3CDK2 | |
| SCHEMBL4279939 | 0.88 | ZAP70 (0.53) | ZAP70JAK2JAK3CDK2 | |
| SCHEMBL4279324 | 0.87 | ZAP70 (0.43) | ZAP70EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL4277403 | 0.87 | ZAP70 (0.43) | ZAP70EGFRPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | ZAP70 24/4885EGFR 795/4885PRKD3 167/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | ZAP70 43/4885EGFR 494/4885PRKD3 121/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | ZAP70 49/4885EGFR 501/4885PRKD3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.